#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15352	16S	1529	1529	100.0	16S.l6.c17.ctg.1	1984	767.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1407	1407	C	924	C	840	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	0	.	n	.	0	A20C	SNP	20	20	A	321	321	C	454	C,A	431,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	0	.	n	.	0	T695C	SNP	695	695	T	996	996	C	859	C	778	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	1939	1939	G	963	G	896	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2272	2272	C	883	C	790	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2346	2346	A	879	A	809	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26600	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3435	771.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2898	2898	C	844	C	778	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2128	folP	855	855	100.0	folP.l6.c4.ctg.1	1360	155.4	1	SNP	p	R229S	1	.	.	685	687	AGC	935	937	AGC	215;216;217	A;G;C	197;202;203	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5774	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3383	170.1	1	SNP	p	S91F	1	.	.	271	273	TTC	603	605	TTC	215;214;215	T;T;C	195;193;196	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5774	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3383	170.1	1	SNP	p	D95G	1	.	.	283	285	GGC	615	617	GGC	215;212;209	G,T;G,C;C	194,1;187,2;188	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5774	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3383	170.1	1	SNP	p	G95N	0	.	.	283	285	GGC	615	617	GGC	215;212;209	G,T;G,C;C	194,1;187,2;188	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1644	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1375	119.1	0	.	p	.	0	F184L	NONSYN	550	552	TTC	947	949	TTG	227;228;226	T;T;G	205;205;203	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1644	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1375	119.1	1	SNP	p	G45D	0	.	.	133	135	GGC	530	532	GGC	203;200;200	G;G,T,A;C	194;188,1,1;190	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	872	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	701	122.3	0	.	n	.	0	A197.	DEL	197	197	A	436	436	A	220	A	205	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5356	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	183.5	1	SNP	p	D86N	0	.	.	256	258	GAC	530	532	GAC	217;216;214	G;A;C	190;186;191	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5356	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	183.5	1	SNP	p	R87W	0	.	.	259	261	CGT	533	535	CGT	215;212;213	C;G;T	189;188;185	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5356	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	183.5	1	SNP	p	S87R	1	.	.	259	261	CGT	533	535	CGT	215;212;213	C;G;T	189;188;185	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5356	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	183.5	1	SNP	p	R87I	0	.	.	259	261	CGT	533	535	CGT	215;212;213	C;G;T	189;188;185	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5356	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2910	183.5	1	SNP	p	S88P	0	.	.	262	264	TCC	536	538	TCC	211;211;211	T;C;C	187;184;184	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4428	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2442	180.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1436	1438	GGC	276;275;272	G;G;C	250;247;240	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1285	1287	GCA	250;252;251	G,A;C;A	222,2;227;227	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1288	1290	ATC	250;252;253	A;T;C	224;222;223	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1300	1302	GTG	251;251;246	G;T,G;G	221;219,1;216	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1300	1302	GTG	251;251;246	G;T,G;G	221;219,1;216	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1804	1806	ACC	227;228;228	A;C;C	209;216;220	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1858	1860	GCG	190;189;188	G;C;G	164;146;152	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1858	1860	GCG	190;189;188	G;C;G	164;146;152	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1981	1983	AGC	191;187;184	A;G;C	175;171;169	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1990	1992	GGC	177;173;173	G;G;C	160;159;157	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4026	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2431	164.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2008	2010	CCG	155;154;154	C,G;C,G;G	113,6;112,1;115	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5896	ponA	2397	2397	99.92	ponA.l15.c4.ctg.1	3258	180.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2366	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1629	143.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	477	477	C	166	C	150	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	969	971	AAT	12;12;12	A;A;T	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	972	974	AAT	12;12;11	A;A;T	12;12;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	996	998	GCA	15;15;15	G;C;A	15;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1019	1021	GTA	16;16;17	G;T;A	16;16;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1025	1027	AAC	17;18;17	A;A;C	17;18;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1029	1033	TGGCG	17;17;17;19;21	T;G;G;C;G	17;17;17;18;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1035	1037	GCT	22;23;27	G;C,T;T	21;21,1;26	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1095	1097	TTA	57;57;57	T;T;A	52;52;52	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1140	1142	CAT	63;61;60	C;A;T	55;54;53	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1143	1145	AGT	62;62;61	A;G;T	55;55;55	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1152	1154	TAC	63;63;62	T;A;C	56;55;56	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	R307A	NONSYN	919	921	AGA	1242	1244	GCA	20;18;18	G;C;A	20;18;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	T311A	NONSYN	931	933	ACA	1254	1256	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	344	porB1a	984	318	90.06	porB1a.l6.c30.ctg.1	1262	25.8	0	.	p	.	0	E312D	NONSYN	934	936	GAA	1257	1259	GAC	16;16;16	G;A;C	16;14;14	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	499	501	GAA	228;229;229	G;A;A	214;216;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	A82V	NONSYN	244	246	GCC	631	633	GTC	201;197;196	G;T;C	182;174;178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	910	912	TCA	212;213;214	T;C;A	196;198;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	N213D	NONSYN	637	639	AAT	1024	1026	GAT	228;227;226	G;A;T	210;209;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1039	1041	GTC	211;209;211	G;T;C	198;192;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1051	1053	TCT	206;209;206	T;C;T	190;191;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1369	1371	GCA	209;205;208	G;C;A	192;188;190	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	1	SNP	p	G120K	1	.	.	358	360	AAG	745	747	AAG	237;238;236	A;A;G	222;220;221	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	1	SNP	p	D121N	0	.	.	361	363	GAC	748	750	GAC	235;230;229	G,C;A;C	218,1;215;212	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1556	168.7	1	SNP	p	A121D	1	.	.	361	363	GAC	748	750	GAC	235;230;229	G,C;A;C	218,1;215;212	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10472	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4995	209.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1122	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	947	118.2	1	SNP	p	V57M	1	.	.	169	171	ATG	500	502	ATG	239;241;239	A;T;G	221;222;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
